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An inﬂammatory-like process and vascular remodeling represent the main changes that
occur in decidua in the early phase of pregnancy. These changes are partly induced by
trophoblast cells that colonize the decidua and are also contributed by the complement
system, which can easily be activated as a result of tissue remodeling. Local control by
several complement regulators including surface-bound and soluble molecules is critical
to prevent complement-mediated tissue damage in normal pregnancy. C7 expressed on
the endothelial cells (ECs) surface has been recognized as a novel complement regulator
involved in the control of the proinﬂammatory effect of the terminal complement complex.
The protective role of placental complement regulators in pregnancy is underscored by the
recent ﬁnding of an association of preeclampsia with mutations in the genes encoding
for some of these proteins. Complement components produced at feto-maternal inter-
face serve an important function in placental development. C1q synthesized by decidual
ECs and expressed on the cell surface is particularly important in this regard because
it acts as a molecular bridge between endovascular trophoblast and ECs. C1q is also
produced by extravillous trophoblast and is used to favor trophoblast migration through
the decidua. Defective expression of C1q by trophoblast is associated with impaired tro-
phoblast invasion of decidua and may have important implications in pregnancy disorders
such as preeclampsia characterized by reduced vascular remodeling.
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INTRODUCTION
During the early phase of pregnancy the endometrium of the
uterus undergoes profound changes and transforms into decidua,
a newly formed tissue that plays a critical role for successful embryo
implantation and regular fetal growth. The decidua provides a
physical anchorage for the implanted embryo tightly attached to
the maternal tissue by means of anchoring villi surrounded by
an outer layer of trophoblasts that form cell columns. Some of
these cells leave the villi and invade the decidua as extravillous
trophoblasts (EVTs) reaching the inner third of the myometrium
where they form multinucleated giant cells (Plaisier, 2011). A dis-
tinct group of EVTs penetrates the uterine spiral arteries and
migrates upward against the blood ﬂow partially replacing the
endothelial cells (ECs) to form mosaic vessels (Bulla et al., 2005;
Figure 1).
Being of fetal origin, villous trophoblasts exposed to mater-
nal blood circulating in the intervillous space and EVTs present
in human decidua represent a real challenge for the maternal
immune system. As a result, a vigorous response may be mounted
against paternal antigens expressed on trophoblasts leading to
potential deleterious effects on fetal survival. To avoid these unde-
sired consequences,different strategies are developed to prevent an
immunologic attack of the mother against the fetus while keeping
intact the protective function against harmful pathogens. Failure
to express classical polymorphic MHC class I and class II mol-
ecules is used by villous trophoblasts to evade recognition by T
cells. Unlike villous trophoblasts, EVTs express MHC molecules,
but these are restricted to class I classical HLA-C and non-classical
HLA-E, HLA-F, and HLA-G proteins that are not usually used to
stimulate T cells.
The mother adopts a different strategy to protect the fetus
organizing a protective environment at site of embryo implan-
tation with the aim to neutralize harmful attack of the fetus by
the maternal immune response. Maternal tolerance of the fetus is
maintained primarily by CD4+ CD25+ regulatory T cells (Aluvi-
hare et al., 2004) with the contribution of CD8+ T cells (Tilburgs
et al., 2010) and NK cells (Hanna et al., 2006), which have recently
been shown to induce formation of T regulatory cells as a result of
physical interactionwith decidualmyelomonocytic CD14+ (Vacca
et al., 2010).
Embryo implantation is associated with an inﬂammatory
process that develops in decidua in response to trophoblast cells
that make their way through the stroma by means of the pro-
teases of the matrix metalloproteinase and plasminogen activa-
tor/plasmin systems (Salamonsen, 1999; Pepper, 2001) to invade
the maternal tissue. Trophoblast invasion of decidua results in
recruitment and activation of leukocytes and precursors of ECs
and in the release of various cytokines, chemokines, growth fac-
tors that promote tissue remodeling (Plaisier, 2011). Hormonal
changes contribute to the development of inﬂammation in mater-
nal decidua in the early pregnancy as suggested by the observation
that a similar process, though less intense, occurs in non-pregnant
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FIGURE 1 | Interstitial and endovascular invasion of trophoblast cells.
(A) Histological section of ﬁrst trimester placenta stained for cytokeratin 7,
showing an anchoring villi (AV). (B)Transmission electron microscope image
of a remodeled vessel in which a trophoblast cell (TC) lines the vascular wall
together with endothelial cells (ECs).
uterus during themid-luteal phase of themenstrual cycle. It should
be pointed out, however, that this process rather than having dele-
terious effects helps to promote fetal survival and somehow resem-
bles the inﬂammation developingwithin the tumormicroenviron-
ment that stimulates tumor progression, tissue remodeling and
angiogenesis, and down-modulates adaptive immune response
(Sica and Bronte, 2007; Le Bitoux and Stamenkovic, 2008).
The cell inﬁltrate present in decidua during normal pregnancy
includes leukocytes that constitute 30% of stromal cells and com-
prise approximately 70% NK cells, 20–25% macrophages, and
1.7% dendritic cells, while T lymphocytes represent about 3–10%
of the decidual immune cells (Vacca et al., 2010). These cells com-
municate with each other and talk to EVTs contributing in this
way to the important changes that occur in decidua. Thus, decid-
ual NK cells have been found to regulate trophoblast invasion
(Hanna et al., 2006) while EVTs recruit decidual NK through the
release of CXCL12 (Hanna et al., 2003; Wu et al., 2005).
A cross-talk is also established between EVTs and other cells
of both innate and adaptive immunity leading to the differenti-
ation of immune cells into a trophoblast-supporting phenotype
through the action of HLA-G expressed by invading trophoblasts
(Shakhawat et al., 2010; Mor et al., 2011). A special interac-
tion occurs between trophoblasts and macrophages that represent
approximately 20–25% of the leukocyte population in decidua.
These cells are stimulated by trophoblasts to remove apoptotic cells
in order to prevent the release of harmful proinﬂammatory and
pro-immunogenic intracellular contents (Abrahams et al., 2004)
and are also educated to secrete cytokines and chemokines that
support trophoblast growth and survival (Fest et al., 2007).
Vascular changes represent an important feature of the decid-
ual tissue in the early phase of pregnancy and are characterized
by active angiogenesis and vascular remodeling involving the spi-
ral arteries. These changes ensure a regular supply of maternal
blood to the developing placenta at an optimal ﬂow rate and are
made possible by the transformation of the spiral arteries into low-
resistance dilated thin-walled vessels as a result of loss of vascular
smooth muscle cells and partial replacement of ECs by endovas-
cular trophoblasts (Lyall et al., 2001; Pijnenborg et al., 2006). Data
collected both in mice (Guimond et al., 1998; Greenwood et al.,
2000), and humans (Smith et al., 2009) suggest that decidual NK
cells clustered around spiral arteries in early pregnancy play a
role in vessel remodeling. Perivascular trophoblasts have also been
shown to contribute to this process inducing degradation of the
internal elastic lamina and medial elastin ﬁbers of the vessel wall
through the action of metalloproteinases MMP-12 (Harris et al.,
2010).
The original idea that pregnancy represents an anti-
inﬂammatory state is no longer tenable in the light of evidence
supporting the concept that a proinﬂammatory environment is
required for embryo implantation and trophoblast invasion (Mor
et al., 2011). The data so far available indicate that the inﬂamma-
tory state is sustained by cytokines and chemokines released by the
cells that accumulate in the decidua. Less attention has been paid
to the contribution of the complement (C) system to the success
of embryo implantation and also to the regular development of
the fetus. In this review we shall examine the double role that C
plays in the pathophysiology of pregnancy focusing in particular
on the local effect of C components and C activation products in
placenta.
PRODUCTION OF C COMPONENTS AND REGULATORS AT THE
FETO-MATERNAL INTERFACE
Although the liver represents the major source of circulating C
components (Morris et al., 1982), evidence collected over the last
three decades indicates that they can also be synthesized at extra-
hepatic sites in various tissues and organs (Morgan and Gasque,
1997). Several cell types have been found to produce C com-
ponents including macrophages (Johnson and Hetland, 1988),
ﬁbroblasts (Garred et al., 1990), ECs (Langeggen et al., 2000) as
well as tissue speciﬁc cells (Brooimans et al., 1991; Dovezenski
et al., 1992; Khirwadkar et al., 1993; Gulati et al., 1994; Andoh
et al., 1998; Grifﬁths et al., 2009; Pattrick et al., 2009). As a result
of the contribution of different cell types to local synthesis of C
components, an entire C system can be organized at tissue sites
that can be readily available for local needs. The C proteins are
secreted locally in limited amount under physiologic conditions,
but their level is expected to meet the special requirements elicited
by pathologic situations that regulate their biosynthesis through
the action of cytokines and other stimuli (Colten and Garnier,
1998).
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Although locally synthesized C components may contribute
to tissue damage, as is the case of C3 produced by renal tubular
epithelium involved in the development of inﬂammation leading
to transplant rejection (Pratt et al., 2002), they play a critical role
in host defense at tissue and organ level (Morgan and Gasque,
1997; Laufer et al., 2001). The protective function of the C system
is particularly important in the female reproductive tract during
pregnancy since the implanted embryo is vulnerable to attack by
pathogens that colonize the cervico-vaginal cavity. It is therefore
not surprising that a local protection is needed to prevent the
access of infectious agents to the feto-placental unit. The recogni-
tion molecules of the C system MBL, C1q, and C3 are present in
the cervico-vaginal cavity where they provide a ﬁrst line of defense
against infectious agents (Pellis et al., 2005). Interestingly, the vagi-
nal epithelium is the main local source of MBL which is secreted
under hormonal control reaching the highest value in the post-
ovulatory phase of the menstrual cycle in close correlation with
the increased level of progesterone.
SeveralC components of both classical and alternative pathways
and C regulators are secreted by chorionic tissue and chorion-
derived cells and their synthesis is differently regulated by various
cytokines (Goldberg et al., 2007). The ability of some of these
cytokines to up-regulate local production of C components and
regulators in normal pregnancy is critical to neutralize invading
pathogens and also to protect the fetus from attack by thematernal
immune system.
Trophoblasts constitute a major component of decidual cells
and contribute to local synthesis of C components in maternal
decidua representing the primary source of C3 and C4 at feto-
maternal interface (Bulla et al., 2009). The expression of these
C components by trophoblast cells is not modulated by IL-1α
and TNF-α but is up-regulated by IFNγ. The latter cytokine pro-
duced at placental level mainly by decidual NK (Lash et al., 2006)
controls trophoblast activation (Gagioti et al., 2000) and inva-
sion into the decidua (Hu et al., 2006; Lash et al., 2006), and
plays a critical role in remodeling spiral arteries in the mouse
(Ashkar et al., 2000). The ﬁnding that trophoblast cells secrete C3
and C4 involved in opsonophagocytosis further supports previ-
ous observations suggesting that these cells help to promote the
innate immune response at the placental level during pregnancy
and potentially contribute to placental immune defense against
pathogens (Amarante-Paffaro et al., 2004). In addition to C3 and
C4, trophoblast cells have been found to secrete C1q (Agostinis
et al., 2010), which is relatively abundant in maternal decidua
being synthesized by other cells including macrophages, ﬁbrob-
last, and ECs. It is important to note that the decidua is the only
tissue where ECs are able to produce C1q in physiologic condi-
tions (Bulla et al., 2008). Interestingly, themolecule synthesized by
decidual ECs (DECs) is expressed to a large extent on the cell sur-
face and onlymarginally secreted. The high avidity binding of C1q
to the cellmembrane is not due to its interactionwith the receptors
for the collagen tail or the globular head of the molecule identiﬁed
on ECs (Peerschke et al., 1996). Removal of a substantial portion
of bound C1q from the cell membrane by treatment with hepari-
nases rather suggests that surface expressed heparan sulfates offer
the binding site for the molecule (Bulla et al., 2008). C7 is another
C component synthesized by ECs (Langeggen et al., 2000) and is
also detected on the membrane of DECs (Figure 2; Bossi et al.,
2009). However, the expression of C7 on the cell surface, unlike
that of C1q, is not restricted to DECs but it is observed also on
the vessel endothelium of several tissues including endometrium
of non-pregnant uterus, skin, kidney, and brain. The expression
level of membrane bound C7 is up-regulated by the proinﬂamma-
tory cytokines I-1α, TNF-α, and IFN-γ. In contrast with bound
C1q, surface expressed C7 cannot be removed by treatment with
heparinases and is associated with vimentin.
NON-CANONICAL ROLE OF THE C SYSTEM IN HUMAN PLACENTA
For a long time C has been viewed as an effector system that, once
recognized the target to neutralize, acts by promoting the inﬂam-
matory process or by inducing cell cytotoxicity. Data accumulated
over the last few years indicate that C components and C acti-
vation products may exhibit alternative functions. The increased
expression of C1q and C4 mRNA in some areas of the rat brain
during the embryonic life is suggestive of a novel role of C in
brain development (Johnson et al., 1994). C3 and C5 have been
implicated in lens regeneration (Kimura et al., 2003), while C3a
and C5a were shown to promote liver regeneration through the
intermediate action of IL-6 and TNFα (Strey et al., 2003).
The decidua is another tissue where C has been found to con-
tribute to tissue remodeling and vascular changes (Bulla et al.,
2008). The recognition that the C system serves non-canonical
functions in human placenta stems from studies showing that
C1q is involved in placental development (Bulla et al., 2008).
More speciﬁcally, C1q was found to play an important role in
the replacement of DECs by endovascular trophoblasts migrating
along the decidual spiral arteries and in trophoblast invasion of
maternal decidua. The original observation that prompted these
studies was the detection of C1q on the surface of DECs in normal
pregnancy in the absence of immunoglobulins and C4. This ﬁnd-
ing was surprising because deposits of C1q are usually observed
in pathologic conditions associated with C activation. Interest-
ingly, C1q was found to be localized at the contact site between
endovascular trophoblasts and DECs suggesting its implication in
the physical interaction between the two cell types. In vitro exper-
iments of adhesion assay conﬁrmed this hypothesis showing that
the adhesion of puriﬁed trophoblasts to a conﬂuent monolayer of
FIGURE 2 | C7 is synthesized and expressed by DECs. (A) Light
microscopy image of a decidual vessel from human ﬁrst trimester placenta.
(B) Confocal analysis of the same decidual vessel stained for C7.
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DECs is prevented by antibodies to C1q. This cell bound C com-
ponent acts as a bridge between endovascular trophoblasts and
decidual endothelium by virtue of its interaction with a receptor
for the globular head of C1q (gC1qR) expressed on trophoblasts.
Binding of trophoblasts to DECs is a rather complex process pro-
moted by severalmolecules includingC1q andVE-cadherin (Bulla
et al., 2005) and is followed by transendothelial migration of tro-
phoblasts that eventually reach the basal membrane and partially
replace ECs.
The ﬁnding that C1q is actively synthesized by EVTs and is
widely distributed in decidual stroma led to the recognition of an
additional function of the early C component in promoting tro-
phoblast migration through the decidua. Trophoblast cells were
found to adhere to C1q and to migrate through an insert of a
transwell coated with C1q that recognizes cell-expressed gC1qR,
as well as a4 and β1 integrins and triggers activation of the MAP
kinases pathway. The in vivo relevance of these ﬁndings is sup-
ported by the observation of impaired labyrinth development and
decreased remodeling of decidual vessel associated with increased
fetal resorption rate, reduced fetal weight, and smaller litter size
observed inC1qKOmice as comparedwithWTanimals (Agostinis
et al., 2010).
REGULATORY FUNCTIONS OF THE C SYSTEM AT THE
FETO-MATERNAL INTERFACE
Extensive remodeling of decidua favors C activation that may lead
to tissue damage and adverse pregnancy outcome. C-dependent
damage of trophoblasts may promote cell destruction or more
likely increased permeability of the barrier, opening the way to
bacteria, virus, and other toxic molecules that compromise fetal
survival. No wonder if decidual cells have developed strategies
to prevent C-mediated damage consisting in the expression of C
regulatory proteins (CRPs) DAF or CD55, MCP or CD46, and
CD59.
Syncytiotrophoblasts that form the outer layer of villous tro-
phoblasts require a particular protection against C activation
products because they are directly exposed to maternal blood
and are therefore at special risk of being attacked by activated C.
These cells express all three regulatory proteins (Holmes et al.,
1990, 1992) and are further protected by the binding of vit-
ronectin or S protein, a soluble inhibitor of the assembling mem-
brane attack complex (MAC) of the C system acquired from the
maternal blood (Tedesco et al., 1990). Villous cytotrophoblasts
form a continuous layer of cells adhering to the basal mem-
brane of the villi below the syncytiotrophoblasts and expressMCP
and CD59, while controversy exists on the expression of DAF
(Holmes et al., 1990, 1992; Hsi et al., 1991). EVTs also express
CRPs on their surface, in particular CD59, while DAF and MCP
are mainly detected on decidual giant cells (Hsi et al., 1991;
Bulla et al., 2003). Endovascular trophoblast cells that colonize
decidual spiral arteries are similarly exposed to maternal blood
and are a potential C target. Damage may also involve ECs and
other cells of maternal origin in decidua, since locally released
C effector molecules do not distinguish between foreign agents
and self components and cause tissue alterations through the
destructive effect of MAC or via promotion of the inﬂammatory
process.
Evidence for the protective functionof the regulatorymolecules
expressed on the surface of syncytiotrophoblasts was obtained in
studies analyzing the susceptibility of these cells to C-dependent
killing induced by antibodies directed against steroid producing
cell that recognize syncytiotrophoblasts (Tedesco et al., 1993).
Antibody-mediated neutralization of CD46 and CD59 expressed
on syncytiotrophoblasts led to a substantial increase in cell killing
emphasizing the important role of the two C regulators in tro-
phoblast protection while CD55 seems to be less critical being
expressed in only 30% of these cells (Tedesco et al., 1993).
Endothelial cells are another potential target of C attack in
decidua and are protected by several CRPs expressed on the cell
surface or acquired from the ﬂuid phase (Fischetti and Tedesco,
2006). Evidence has been collected supporting an additional pro-
tective mechanism used by ECs to control the proinﬂammatory
effects of the terminal complex SC5b-9. This complex is assembled
in the ﬂuid phase as a result of C activation and can be detected
both in plasma and in the extravascular ﬂuids as a cytolytically
inactive complex (Bossi et al., 2009). We have previously shown
that this inactive complex, despite its failure to cause cell dam-
age, is still able to bind to ECs and stimulate the cells to express
adhesion molecules and tissue factor (TF; Tedesco et al., 1997), to
release chemokines (Dobrina et al., 2002), to induce transendothe-
lial migration of PMN (Dobrina et al., 2002), and to promote
vascular leakage (Bossi et al., 2004). Protection against the dam-
aging effect of the assembling terminal C complex is provided by
EC-bound C7, that acts as a trapping molecule for excess C5b6
complex released in the ﬂuid phase under conditions of unre-
stricted C activation during acute phase response. Subsequent
binding of C8 and C9 leads to the assembly of a cytolytically inac-
tive membrane bound terminal complex (mTCC), that contains
also S protein and clusterin and is cytolytically inactive. How-
ever, unlike soluble SC5b-9, mTCC fails to activate ECs, and in
addition down-regulates cell activation induced by SC5b-9 mod-
ulating the expression of adhesion molecules, the release of IL-8,
and EC permeability (Bossi et al., 2009). ECs normally utilize GPI-
anchored molecule CD59 to neutralize the C-mediated cell lysis
caused by the assembling MAC, but this C regulator has no effect
on the damaging effect of the soluble complex SC5b-9 which can
only be controlled by mTCC. Tight control of C activation by
several regulators is particularly important at feto-placental site
where direct C-mediated damage and indirect effect associated
with excessive inﬂammationmay impair fetal growth and possibly
lead to miscarriage (Christiansen et al., 2006).
The importance of C regulation at the embryo implantation
site is emphasized by the data obtained in murine models of preg-
nancy failure. Xu et al. (2000) made the original observation that
Crry deﬁciency in utero leads to progressive embryonic lethality
and Crry−/− embryos are surrounded by activated C3 fragments
and PMN. Crry is expressed on fetal trophoblast cells and mater-
nal decidua, where it controls deposition of C3 and C4 on the cell
surface, preventing formation of the cytolytic MAC (Weigle et al.,
1983; Molina et al., 1992; Kim et al., 1995). The critical role played
by C activation products in causing fetal loss in Crry−/− mice is
supported by the ﬁnding that the embryos are completely rescued
from lethality and live pups are born at a normal Mendelian fre-
quency when Crry+/− parents are intercrossed with C3−/−mice
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to generate C3−/−, Crry−/− embryos (Xu et al., 2000). This out-
come is a genetic proof that Crry−/− embryos die in utero due to
their inability to suppress C activation and tissue damage medi-
ated by C3. The C regulator Crry has also been shown to control
fetal resorption in a murine model of antibody-mediated anti-
phospholipid syndrome (APS; Holers et al., 2002), as suggested
by the ability of human IgG containing anti-phospholipid anti-
bodies (aPL) injected into pregnant mice to cause fetal resorption
in C sufﬁcient animal, but not in C3 deﬁcient mice. Protection
against fetal loss was also observed in mice that received recombi-
nant Crry-Ig to prevent C activation through the inhibition of C3
convertase.
There is some indication that C regulators contribute to protect
the feto-placental unit also in human APS. Francis et al. (2006)
reported an impaired endometrial expression of DAF/CD55 in
patients with recurrent pregnancy loss associated with APS sug-
gesting that the abnormal expression of this C regulator before
conception may compromise implantation and predisposes to
C-mediated pregnancy failure.
A protective role for C regulators has also been established in
animal models of PE developed in CBA/J females mated to DBA/J
males. These mice manifest many features of human PE, such as
primigravidity, albuminuria, glomerular endotheliosis, increased
sensitivity to angiotensin II and increased plasma leptin levels,
correlated with bad pregnancy outcome (Ahmed et al., 2010).
Administration of Crry to pregnant DBA/2 CBA/J mice helped
to reduce the level of proteinuria, and blood urea nitrogen, ﬁb-
rin deposition, and glomerular endotheliosis (Qing et al., 2011),
supporting the concept that local C activation is deleterious to the
developing fetus.
The importance of the C regulators in patients with PE has
recently been underscored by Salmon et al. (2011),who performed
a prospective study of 250 pregnant patients with SLE and/or
APL antibodies to identify predictors of pregnancy outcome. They
sequenced the genes encoding three C control proteins, MCP,
factor H (CFH), and Factor I (CFI) and found heterozygousmuta-
tions in 7 out of 40 patients who developed PE. Based on these
ﬁndings, they concluded that mutations in MCP and CFI predis-
pose to the development of PE, as already observed in patients
with atypical hemolytic uremic syndrome, and that dysregulation
of C activation represents a risk factor for PE.
ROLE OF C IN PATHOLOGIC PREGNANCY
It is commonly believed that C contributes to tissue damage in
pathologic conditions through the destructive activity of MAC or
the proinﬂammatory effect of C5a and other activation products
including the non-cytolytic complex SC5b-9. Placenta is partic-
ularly susceptible to C-dependent damage because trophoblast
exposure to maternal blood and extensive tissue remodeling in
maternal decidua promote C activation during physiologic preg-
nancy. Unrestricted local activation of the system may over-
come the control of CRPs resulting in pregnancy failure or poor
pregnancy outcome.
ANTI-PHOSPHOLIPID SYNDROME
Anti-phospholipid syndrome has received special attention in the
last few years with the establishment of animal models that have
revealed the involvement of C in the onset of the twomain clinical
manifestations of the syndrome represented by fetal loss and vas-
cular thrombosis (Holers et al., 2002; Fischetti et al., 2005; Girardi
et al., 2006). Pregnancy failure in the mouse model of APS has
been attributed to the release of C5a and recruitment of PMN fol-
lowed by TF-dependent promotion of coagulation as a result of C
activation induced by APL (Girardi et al., 2003; Ritis et al., 2006;
Redecha et al., 2007). The serumproteinβ2-glycoprotein I (β2GPI)
represents the main target of these antibodies once bound to the
cell surface of trophoblasts and ECs (Pierangeli et al., 2008;Meroni
et al., 2011). Binding of β2GPI to trophoblasts and ECs in placenta
occurs spontaneously, but its interaction with the endothelium of
other tissues such as brain and gut requires priming with LPS
(Agostinis et al., 2011a).
While the contribution of the C system to fetal loss and throm-
bosis in animal models is well established, the role played by C
in mediating tissue damage in human APS is less clear, though
this is suggested by the ﬁnding of C deposition in placental tissue
from patients with aPL (Girardi et al., 2006). Analysis of placentae
obtained from a large number of APS patients by Shamonki et al.
(2007) revealed increased deposition of C4d in the cytoplasm of
villous trophoblasts correlated with the histologic alterations of
APS placentae. An essentially similar conclusion was reached by
Cohen et al. (2011),who founddiffuseC4ddeposits on villous syn-
cytiotrophoblasts of placentae from patients with SLE and/or APS
suggestive of adverse pregnancy outcome. The relevance of C5b-9
deposits in APS patients is somewhat controversial since the local
level of this complex was found to be lower in APS patients com-
pared with that of the control group (Shamonki et al., 2007). In a
recent prospective study on full-term placentae from patients with
primary APS and normal control we were able to reveal marked
C5b-9 deposits that were only weak or undetectable in the con-
trol group, although the presence of the complex was not always
related to pregnancy outcome or therapy (Meroni et al., 2011).
PREECLAMPSIA
This is a multifactorial pathological condition of pregnancy that
affects 3%–5% of all pregnancies and is characterized by hyper-
tension and proteinuria. The C system has been implicated in
the development of PE placental alterations together with other
pathogenic factors. Activation products of both early and late C
components have been detected in the circulation of PE patients
and the split product Bb has been proposed as a marker for high
risk of PE (Lynch et al., 2008), though there is no general agree-
ment on this issue (Derzsy et al., 2010). Deposits of C components
including late components and their activation products respon-
sible for promotion of inﬂammation and tissue damage have been
documented in PE placenta, in particular in chorionic villi, in
inter- andperi-villus ﬁbrin surrounding syncytiotrophoblasts, and
inmaternal decidua (Sinha et al., 1984; Tedesco et al., 1990;Girardi
et al., 2006). Despite the failure to detect increased activity of the
MBL–MASP2 complex in the PE patients (Csuka et al., 2010),
two activators of the lectin pathway (LP) H-ﬁcolin and L-ﬁcolin
have been detected on syncytiotrophoblasts of PE placentae (Wang
et al., 2007) suggesting an association of the placental abnormali-
ties with the activation of this pathway. The involvement of LP of
C activation is further supported by the ﬁnding that MBL-A, one
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of the twomurineMBL proteins, is deposited on the implantation
sites of CBA/J females mice mated with DBA/2 males, a abortion-
prone mating combination recognized as a murine model of PE
(Ahmed et al., 2010).
Besides inducing tissue damage, theC systemhas been shown to
exert a physiologic role contributing to promote tissue remodeling
in maternal decidua. This process is defective in PE characterized
by the persistence of unremodeled spiral arteries and poor pla-
centation (Redman and Sargent, 2010). Following the observation
that C1q promotes trophoblast invasion of maternal decidua and
that C1q deﬁciency is associated with impaired labyrinth devel-
opment and decidual vessel remodeling in pregnant mice, Singh
et al. (2011) have recently shown that pregnant C1q−/− deﬁcient
micemanifest the essential features of human PE including hyper-
tension, albuminuria, endotheliosis, decreased placental vascular
endothelial growth factor (VEGF), and elevated levels of soluble
VEGF receptor 1 (sFlt-1). Our preliminary data showing failure of
trophoblasts surrounding unremodelled spiral arteries in human
PE decidua to synthesize and secrete C1q suggest that the obser-
vations in C1q−/− deﬁcient mice may be relevant to human PE
(Agostinis et al., 2011b).
CONCLUSION
The contribution of the C system to host defense and tissue
damage mediated through the inﬂammatory process and cell
cytotoxicity is well established. More recently, alternative func-
tions on cells and tissues have been identiﬁed involving both
native components and C activation products. The C system
has been shown to contribute to tissue regeneration and brain
development through the action of C3, C5, and their activation
fragments. C1q is emerging as one of the C components able
to exert functions independent on C activation. Several cell tar-
gets have been found to respond to C1q including cell of innate
and acquired immunity as well as other cells not directly involved
in the immune response. Most of the information available on
this issue have been obtained in in vitro studies using puriﬁed
C1q. The pitfall of these studies is that C1q detected in plasma
and in extravascular ﬂuid is bound to C1r and C1s to form a
complex. Cells synthesizing C1q at tissue level represent a source
of free C component that may exert alternative functions. This
is the case of trophoblasts and DECs that secrete C1q at the
embryo implantation site and contribute to its widespread dis-
tribution in decidual stroma. C1q has been shown to play a
critical role in placental development favoring interaction between
trophoblasts and DECs and promoting EVT migration. The rel-
evance of these in vitro effects is underscored by the ﬁndings of
impaired labyrinthdevelopment anddecidual vessel remodeling in
C1q−/− pregnant mice that have important implications in preg-
nancy disorders such as PE associated with defective trophoblast
invasion.
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